2022
Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer
Leone JP, Hassett MJ, Leone J, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Lin NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer 2022, 128: 3796-3803. PMID: 36069365, PMCID: PMC9826058, DOI: 10.1002/cncr.34448.Peer-Reviewed Original ResearchConceptsPathologic complete responseFive-year OSNeoadjuvant chemotherapyMale breast cancerBreast cancerTumor subtypesOverall survivalIndependent associationEfficacy of NACInitiation of NACHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2National Cancer DatabaseGrowth factor receptor 2Multivariable logistic regressionFemale breast cancerFactor receptor 2HR-/HER2Complete responseMedian timeMultivariable analysisKaplan-MeierCancer DatabaseReceptor 2Logistic regression
2021
Tumor subtypes and survival in male breast cancer
Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Leone JP. Tumor subtypes and survival in male breast cancer. Breast Cancer Research And Treatment 2021, 188: 695-702. PMID: 33770314, DOI: 10.1007/s10549-021-06182-y.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalOverall survivalTumor subtypesBreast cancerHormone receptorsWorse breast cancer-specific survivalMultivariate Cox proportional hazards analysisCox proportional hazards analysisPurposeMale breast cancerTumor subtype distributionCancer-specific survivalProportional hazards analysisInvasive breast cancerMale breast cancerAggressive tumor biologyCox hazard ratiosPopulation-based informationTN diseaseAdvanced diseaseHazard ratioHR-/HER2Inferior survivalMedian agePatient characteristicsPrognostic factors
2020
Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.
Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of Clinical Oncology 2020, 38: 587-587. DOI: 10.1200/jco.2020.38.15_suppl.587.Peer-Reviewed Original ResearchFemale breast cancerPathologic complete responseNeoadjuvant chemotherapyOverall survivalClinical responseTumor subtypesBreast cancerWorse OSExact testHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusEfficacy of NACInitiation of NACNational Cancer Database studyComplete clinical responseHormone receptor statusMale breast cancerLog-rank testFisher's exact testHR-/HER2Complete responseMedian ageReceptor statusMedian timeClinical stagePrevalence and mutational determinants of high tumor mutation burden in breast cancer
Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals Of Oncology 2020, 31: 387-394. PMID: 32067680, DOI: 10.1016/j.annonc.2019.11.010.Peer-Reviewed Original ResearchConceptsHigh tumor mutation burdenTumor mutation burdenPD-1 inhibitorsBreast cancerMutation burdenMedian tumor mutation burdenDifferent mutational signaturesPembrolizumab-based therapyMetastatic breast cancerSubset of patientsMut/MbMismatch repair deficiencyGenomic profilesMutational patternsAPOBEC activityGene panel sequencingMultiple tumor typesWhole-exome sequencingDe-identified dataDurable responsesMetastatic tumorsPrimary tumorTumor subtypesPatientsTumor types
2019
Breast Cancer Treatment
Waks AG, Winer EP. Breast Cancer Treatment. JAMA 2019, 321: 288-300. PMID: 30667505, DOI: 10.1001/jama.2018.19323.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNonmetastatic breast cancerTriple-negative tumorsBreast cancerSystemic therapyTumor subtypesMetastatic triple-negative breast cancerHormone receptor-positive tumorsBreast cancer-specific survivalHuman epidermal growth factor 2Epidermal growth factor 2Small-molecule inhibitor therapyMajor tumor subtypesCancer-specific survivalMedian overall survivalProgesterone receptor expressionMetastatic breast cancerTime of diagnosisReceptor-positive tumorsBreast cancer treatmentErbB2-positive tumorsPreoperative treatment responseERBB2 gene amplificationDistinct risk profilesPalliating symptoms
2017
Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.
Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 316-324. PMID: 28275032, DOI: 10.6004/jnccn.2017.0031.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerDe novo metastatic breast cancerNovo metastatic breast cancerTM testingPET/PET-CTTumor markersBreast cancerPET-CTDisease sitesDana-Farber Cancer InstituteSerum tumor markersTiming of imagingPET-CT scanFrequency of imagingCourse of treatmentPatterns of utilizationAsymptomatic patientsNeurologic symptomsRetrospective cohortClinicopathologic factorsTreatment initiationRadiographic studiesCancer InstitutePatientsTumor subtypes
2014
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal Of Clinical Oncology 2014, 32: 2142-2150. PMID: 24888816, PMCID: PMC4076026, DOI: 10.1200/jco.2013.53.1608.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm StagingPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTrastuzumabTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesConceptsDistant relapse-free survivalBN0M0 breast cancerHER2-negative tumorsBreast cancerT1a tumorsCohort studyT1b tumorsSurvival outcomesHR-positive/HER2-negative tumorsTumor subtypesNational Comprehensive Cancer Network databaseHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusHER2-negative breast cancerNode-negative breast cancerHormone receptorsConsideration of chemotherapyHER2-negative diseasePercent of patientsReceipt of chemotherapyNonrandomized cohort studyProspective cohort studyRelapse-free survivalRate of recurrenceMulti-institutional studyUse and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTriple Negative Breast NeoplasmsConceptsMetastatic breast cancerDuration of chemotherapyLines of therapyBreast cancerTumor subtypesDana-Farber Cancer InstituteSixth-line therapyMedian overall survivalBenefit of chemotherapyResult of progressionWarrants further studyChemotherapy linesChemotherapy regimenProlonged therapyMBC diagnosisMedian durationOverall survivalClinicopathologic characteristicsConsecutive patientsMedian ageClinical benefitMedical recordsChemotherapyCancer InstitutePatients
2011
P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.
Partridge A, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. Cancer Research 2011, 71: p1-08-05-p1-08-05. DOI: 10.1158/0008-5472.sabcs11-p1-08-05.Peer-Reviewed Original ResearchMultivariate Cox proportional hazards modelEarly-stage breast cancerCox proportional hazards modelStage breast cancerProportional hazards modelBreast cancerEstrogen receptorYoung womenProgesterone receptorStratified analysisOlder womenHazards modelTumor subtypesYounger ageBreast cancer-specific survivalHER-2/neu statusCancer-specific survivalER-positive diseaseIndependent risk factorEarly breast cancerER-negative diseaseAge 40 yearsBreast cancer recurrenceEfficacy of therapyBreast cancer biology
2008
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin NU, Winer EP. Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal Of Clinical Oncology 2008, 26: 798-805. PMID: 18258989, DOI: 10.1200/jco.2007.15.0946.Peer-Reviewed Original ResearchConceptsPostmenopausal womenAromatase inhibitorsEndocrine therapyBreast cancerHormone receptor-positive breast cancerHormone receptor-positive cancersInitial breast cancer diagnosisReceptor-positive breast cancerMost postmenopausal womenUpfront aromatase inhibitorsYears of tamoxifenAdjuvant endocrine therapyDisease-free survivalReceptor-positive cancersCommon tumor subtypeBreast cancer diagnosisPostmenopausal settingEndocrine treatmentOverall survivalDisease recurrenceRandomized trialsAvailable trialsIndividual patientsHigh riskTumor subtypes
2007
Brain Metastases: The HER2 Paradigm
Lin NU, Winer EP. Brain Metastases: The HER2 Paradigm. Clinical Cancer Research 2007, 13: 1648-1655. PMID: 17363517, DOI: 10.1158/1078-0432.ccr-06-2478.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerCNS diseaseBreast cancerCentral nervous system metastasesExtra-CNS diseaseImportant sanctuary siteNervous system metastasesProportion of patientsTerms of prognosisCNS metastasesCNS progressionBrain metastasesCytotoxic chemotherapySystemic therapyAdvanced cancerTherapeutic challengePrimary diagnosisHistorical controlsTargeted therapyPreventive strategiesSanctuary siteTumor subtypesParticular tumor subtypesPatientsNatural history